- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04951856
Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI (AMUNDSEN)
Acute Myocardial Infarction Upbound to PCI Immediately (STEMI) or in the Next Three Days (NSTEMI), and Randomized to Subcutaneous Evolocumab or Normal Strategies to Reach Guidelines LDL Objectives in the Real-world - The AMUNDSEN-real Study
AMUNDSEN-real is a phase IV, international (7 European countries), multicenter, controlled, open label study randomized, in 2 parallel groups of patients with a diagnosis of STEMI or NSTEMI with an indication for PCI, using the PROBE study design (Prospective Randomised Open, Blinded Endpoint).
The objective of this study is to demonstrate the superiority of evolocumab versus standard of care in reaching a LDL-C reduction of ≥ 50% from baseline and a LDL-C goal of <1.4 mmol/L (<55 mg/dL) at 12 months follow-up on the overall population.
Central randomization uses an IWRS. Stratification is by center and stratum with random block size, generated according to the procedures of the sponsor, by a statistician not involved in the study.
Study Overview
Status
Intervention / Treatment
Detailed Description
Previous randomized studies and several meta-analyses have shown a positive effect of high-dose statins pretreatment on peri-procedural Myocardial Infarction (MI) incidence with favorable trends on mortality in both Acute Coronary Syndrome (ACS) and stable Coronary Artery Disease patients.
Numerous epidemiological studies, Mendelian randomization studies, and Randomized Controled Trials have consistently demonstrated a log-linear relationship between the absolute changes in plasma LDL-C and the risk of Cardio-Vascular (CV) disease. The effect of LDL-C on the risk of a new CV event appears to be determined by the absolute magnitude, the duration of exposure to LDL-C and possibly the time to reach the recommended target of low LDL in ACS patients.
There are good reasons to believe that the Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors could provide additional benefits when used early in MI patients treated with PCI revascularization.
That's why the hypothesis of AMUNDSEN study is to demonstrate the superiority of a strategy using evolocumab before PCI in STEMI or NSTEMI patients versus standard of care (SOC) as described in the 2019 European Society of Cardiology / European Atherosclerosis Society (ESC/EAS) guidelines on dyslipidemia, to reach a Low-Density Lipoprotein Cholesterol (LDL-C) reduction of ≥ 50% from baseline and a LDL-C goal of <1.4 mmol/L (<55 mg/dL) at the end of the study (LDL targets of the 2019 ESC/EAS guidelines).
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Gilles MONTALESCOT, Pr
- Phone Number: 00 33 01 42 16 30 07
- Email: gilles.montalescot@aphp.fr
Study Locations
-
-
-
Paris, France, 75013
- Recruiting
- ACTION Group, Institut de Cardiologie, Centre Hospitalier Universitaire Pitié Salpêtrière (APHP), UPMC
-
Contact:
- Gilles MONTALESCOT, Pr
- Phone Number: 0033 01 42 16 30 07
- Email: gilles.montalescot@aphp.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Participant meeting all of the following criteria will be considered for enrolment into the study:
- Male or female
Diagnosis of STEMI or NSTEMI
STEMI defined as:
- symptoms of acute MI of at least 30 min AND
- within the previous 24 hours with new persistent ST-segment elevation ≥1 mm in ≥2 continuous ECG leads AND
- an indication for primary PCI AND
- > 55 years
NSTEMI defined as:
- Age≥18
- a history of chest discomfort or ischemic symptoms of ≥10 minutes duration at rest ≤48 hours prior to entry into the study with no evidence of persistent ST-segment elevation and with an elevated troponin (≥ the upper limit of normal according to local laboratory norms), AND
- indication for a coronary angiogram within 72hrs AND
- indication for PCI AND
- at least one the following high-risk characteristics: Diabetes Peripheral Artery Disease Multivessel (≥ 2 or LM) disease on the coronary angiogram History of MI or stroke without sequels prior to randomization eGFR: 15 to 45 mL/min/1.73 m2 calculated with MDRD formula at randomization
- Statin at maximal tolerated dose, as part of the standard of care at randomization
- Informed consent obtained in writing at enrolment into the study
Exclusion Criteria:
Participant presenting with any of the following will not be included in the study:
- Fibrinolysis treatment
- Planned CABG
Ongoing hemodynamic instability defined as any of the following:
- Killip Class III or IV
- Sustained and/or symptomatic hypotension (systolic blood pressure < 80 mm Hg)
- Known left ventricular ejection fraction < 30%
- Evidence of severe hepatobiliary disease: current active hepatic dysfunction or active biliary obstruction, decompensated cirrhosis or infectious/inflammatory hepatitis
- Active malignancy
- A comorbid condition with an estimated life expectancy of ≤ 12 months
- Previously received or receiving evolocumab or any other therapy to inhibit PCSK9
- Known sensitivity to any of the products or components to be administered during study
- Female subject is pregnant, had a positive pregnancy test at inclusion, breastfeeding, or planning to become pregnant or breastfeed during treatment and for an additional 17 weeks after the last dose of IMP
- Currently receiving treatment in any other investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(ies).
- Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the participant and investigator's knowledge.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Evolocumab + SOC
Investigational Product is open label Evolocumab (Repatha®) 140 mg every two weeks: first subcutaneous injection at the time of randomization, before PCI, followings during 12 months.
|
Evolocumab (Repatha®) 140 mg every two weeks: first subcutaneous injection at the time of randomization, before PCI, followings during 12 months.
Other Names:
|
Active Comparator: Standard of care (SOC)
management as recommended in ESC/EAS 2019 guidelines, within reimbursement criteria
|
management as recommended in ESC/EAS 2019 guidelines, within reimbursement criteria
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LDL-C reduction of ≥ 50% from baseline and a final LDL-C of <1.4 mmol/L (<55 mg/dL) at 12 months follow-up.
Time Frame: From baseline and at 12 months
|
Monitoring of changes in LDL-C levels
|
From baseline and at 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LDL-C reduction of ≥ 50% from baseline and a final LDL-C of <1.4 mmol/L (<55 mg/dL) at 12 months follow-up, country by country.
Time Frame: From baseline and at 12 months
|
The same rules as above for the primary endpoint, will apply.
|
From baseline and at 12 months
|
LDL-C reduction of ≥ 50% and an LDL-C goal of <1.4 mmol/L (<55 mg/dL)
Time Frame: From baseline to 6 weeks and 22 weeks
|
Monitoring of changes in LDL-C levels
|
From baseline to 6 weeks and 22 weeks
|
Percent change in levels of LDL-C
Time Frame: From baseline to 6 weeks, 22 weeks and 12 months
|
Monitoring of changes in LDL-C levels
|
From baseline to 6 weeks, 22 weeks and 12 months
|
Time to achieve LDL-C target
Time Frame: Up to 12 months
|
Monitoring of changes in LDL-C levels
|
Up to 12 months
|
Time averaged LDL-C change
Time Frame: Up to 12 months
|
Monitoring of changes in LDL-C levels
|
Up to 12 months
|
Change on total cholesterol
Time Frame: At baseline, 6 weeks, 22 weeks and 12 months
|
Monitoring of changes in cholesterol levels
|
At baseline, 6 weeks, 22 weeks and 12 months
|
Change on HDL-C
Time Frame: At baseline, 6 weeks, 22 weeks and 12 months
|
Monitoring of changes in HDL-C levels
|
At baseline, 6 weeks, 22 weeks and 12 months
|
Change on triglycerides
Time Frame: At baseline, 6 weeks, 22 weeks and 12 months
|
Monitoring of changes in triglycerides levels
|
At baseline, 6 weeks, 22 weeks and 12 months
|
Change on non-HDL-C
Time Frame: At baseline, 6 weeks, 22 weeks and 12 months
|
Monitoring of changes in non-HDL-C levels
|
At baseline, 6 weeks, 22 weeks and 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite of death or any hospitalization for a Cardiovascular (CV) reason
Time Frame: Up to 12 months
|
Data obtained from reported adverse events occurred during participation to the study
|
Up to 12 months
|
Composite of death, MI, stroke, unplanned revascularization
Time Frame: Up to 12 months
|
Data obtained from reported adverse events occurred during participation to the study
|
Up to 12 months
|
Individual endpoints of the composite endpoint above (death, MI, Stroke, unplanned revascularization)
Time Frame: Up to 12 months
|
Data obtained from reported adverse events occurred during participation to the study
|
Up to 12 months
|
Pooled analysis of relationship between time to achieve LDL-C goal and death or any hospitalization for a CV reason
Time Frame: Up to 12 months
|
Data obtained from reported adverse events occurred during participation to the study and LDL-C levels
|
Up to 12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Gilles MONTALESCOT, Pr, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Myocardial Infarction
- Infarction
- ST Elevation Myocardial Infarction
- Non-ST Elevated Myocardial Infarction
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Protease Inhibitors
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Serine Proteinase Inhibitors
- PCSK9 Inhibitors
- Evolocumab
Other Study ID Numbers
- 201075
- 2021-000573-80 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NSTEMI - Non-ST Segment Elevation MI
-
Newcastle-upon-Tyne Hospitals NHS TrustNewcastle University; British Heart FoundationActive, not recruitingNSTEMI - Non-ST Segment Elevation MIUnited Kingdom
-
Stony Brook UniversityHennepin County Medical Center, MinneapolisUnknownAcute Coronary Syndrome | STEMI | NSTEMI - Non-ST Segment Elevation MI | Non ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Coronary Artery Thrombosis (Diagnosis) | Non ST Segment Elevation Acute Coronary Syndrome and other conditionsUnited States
-
Marco MarchettiFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico; Abbott; Azienda Socio... and other collaboratorsCompleted
-
Azienda Ospedaliero Universitaria di SassariAstraZenecaCompletedST Elevation Myocardial Infarction | NSTEMI - Non-ST Segment Elevation MIItaly
-
Karolinska InstitutetCompletedNSTEMI - Non-ST Segment Elevation MI | STEMI - ST Elevation Myocardial InfarctionSweden
-
Charite University, Berlin, GermanyTerminatedAcute Coronary Syndrome | NSTEMI - Non-ST Segment Elevation MI | STEMI - ST Elevation Myocardial InfarctionGermany
-
Maastricht University Medical CenterVieCuri Medical CentreRecruitingNSTEMI - Non-ST Segment Elevation MI | ACS - Acute Coronary SyndromeNetherlands
-
IsalaCompletedCoronary Artery Disease | NSTEMI - Non-ST Segment Elevation MI | STEMI - ST Elevation Myocardial InfarctionNetherlands
-
Qilu Hospital of Shandong UniversityEnrolling by invitationNSTEMI - Non-ST Segment Elevation MI | Acute Heart Failure | Early ManagementChina
-
Abbott Medical DevicesAbbottCompletedCoronary Artery Disease | Atherosclerosis | Coronary Stenosis | STEMI | NSTEMI - Non-ST Segment Elevation MI | STEMI - ST Elevation Myocardial InfarctionUnited States, Spain, Australia, United Kingdom, Canada, New Zealand, Denmark, Switzerland, Germany, Netherlands, India, Japan, Italy, Belgium, France, Hong Kong, Portugal, Singapore, Sweden, Taiwan
Clinical Trials on Evolocumab 140 MG/ML
-
First Affiliated Hospital Xi'an Jiaotong UniversityCompleted
-
University Hospital Inselspital, BerneAmgen; University of BernCompletedAcute Coronary SyndromeSwitzerland
-
University Hospital, GrenobleRecruiting
-
Radboud University Medical CenterAmgenRecruitingCoronary Artery Disease | Atherosclerosis of Coronary ArteryNetherlands
-
University of Campinas, BrazilCompletedDiabetes Mellitus, Type 2 | Dyslipidemia Associated With Type II Diabetes Mellitus | Hypertension ArterialBrazil
-
Wuhan Union Hospital, ChinaRecruitingHigh-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized StudyCerebral AtherosclerosisChina
-
Leonardo ClavijoAmgenUnknownPeripheral Arterial DiseaseUnited States
-
Henan Institute of Cardiovascular EpidemiologyRecruitingST Elevation Myocardial Infarction (STEMI)China
-
Merck Sharp & Dohme LLCTerminated
-
Novo Nordisk A/SCompletedAtherosclerotic Cardiovascular DiseaseGermany, Poland, United States, Netherlands, Japan, Greece, Belgium